Back

Safety profile of novel angiotensin II type-1 receptor neprilysin inhibitor lcz696 (sacubitril/valsartan) - a collaborative summary from clinical trials

29 May 2018 (08:00 - 12:30)
Organised by:
Congress Presentation Part of: Poster Session 4 - Chronic Heart Failure – Treatment Pharmacotherapy HFA Premium Access Heart Failure 2018

About the speaker

Photo
Doctor Adhiala Zyggo Barano

Badau Bergerak Hospital, Kapuas Hulu (Indonesia)

21 More presentations in this session

Presentation thumbnail
Professor Q. Hua (Beijing, CN)
Presentation thumbnail
Mrs H. Norberg (Umea, SE)
Abstract Slides
Presentation thumbnail
Doctor L. Lupi (Brescia, IT)
Abstract
Presentation thumbnail
Doctor F. Melillo (Milan, IT)
Abstract
Presentation thumbnail
Doctor J. Neiva (Viana do Castelo, PT)
Abstract

Access the full session

Session thumbnail
Poster Session 4 - Chronic Heart Failure – Treatment

The Event

Event poster

Heart Failure 2018

29 May 2018 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of sacubitril valsartan in heart failure compared to renin angiotensin aldosterone system inhibitors: a systematic review and meta analysis of randomised controlled trials
26 August 2022
thumbnail
Congress Session
Practice-changing studies from NEJM 2022-2023
27 August 2023
thumbnail
Congress Presentation
Safe electrophysiologic profile of the neprilysin-inhibitor sacubitril in combination with different antiarrhythmic drugs
29 August 2022
thumbnail
Congress Presentation
1 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources